- Trials with a EudraCT protocol (1,307)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (116)
1,307 result(s) found for: Bone scan.
Displaying page 1 of 66.
EudraCT Number: 2007-000885-20 | Sponsor Protocol Number: Ibondronate | Start Date*: 2007-07-20 |
Sponsor Name:academic hospital Maastricht | ||
Full Title: Open label study to establish the efficacy of intravenous loading doses of Ibandronate 6 mg in patients with lung cancer and skeletal metastased experiencing moderate to severe bone pain. | ||
Medical condition: Patients with lung cancer and malignant disease to bone. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003771-19 | Sponsor Protocol Number: 2019-100 | Start Date*: 2019-11-19 | |||||||||||
Sponsor Name:Aarhus Universitetshospital | |||||||||||||
Full Title: The effect of improved insulin sensitivity on bone turnover markers and bone biomechanical properties in persons with type 2 diabetes mellitus | |||||||||||||
Medical condition: Type 2 diabetes mellitus Diabetic bone disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000697-74 | Sponsor Protocol Number: ML20115 | Start Date*: 2006-08-07 |
Sponsor Name:The BONiFIN study group | ||
Full Title: A phase II, open label study to establish the safety and efficacy of intravenous loading dose of 3 x Bondronat 6 mg in 3 consecutive days in patients with breast cancer and skeletal metastases expe... | ||
Medical condition: Treatment of pain in breast cancer patients with bone metastases | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005181-31 | Sponsor Protocol Number: A4091003 | Start Date*: 2009-04-29 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES | |||||||||||||
Medical condition: PAIN DUE TO BONE METASTASES | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LV (Completed) SK (Completed) FR (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004316-73 | Sponsor Protocol Number: 3189 | Start Date*: 2006-08-23 |
Sponsor Name:Royal Liverpool University hospital | ||
Full Title: The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A ... | ||
Medical condition: Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003441-16 | Sponsor Protocol Number: ML20570 | Start Date*: 2006-12-12 | |||||||||||
Sponsor Name:N.V. Roche S.A. | |||||||||||||
Full Title: OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS LOADING DOSE OF 3X 6MG IBANDRONIC ACID (BONDRONAT®) DURING 3 CONSECUTIVE DAYS IN PATIENTS WITH BREAST CANCER AND SKELETAL METASTA... | |||||||||||||
Medical condition: Metastasic bone pain in patients with breast cancer and bone metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001855-12 | Sponsor Protocol Number: BO 18040 | Start Date*: 2004-02-16 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal ... | ||
Medical condition: Metastatic Bone Pain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-001854-10 | Sponsor Protocol Number: BO18039 | Start Date*: 2005-02-16 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in... | ||
Medical condition: Metastatic Bone Pain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-001395-38 | Sponsor Protocol Number: CALIPSO-study | Start Date*: 2017-08-03 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA USL DELLA VALLE D'AOSTA | ||||||||||||||||||||||||||||
Full Title: Treatment of Metastatic prostate cancer castration resistant (mCRPC) with 223RaCl2: response evaluation with a novel tracer 68Ga-PSMA PET molecular imaging | ||||||||||||||||||||||||||||
Medical condition: Patients mCRPC eligible to treatment with 223RaCl2 | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000520-35 | Sponsor Protocol Number: ASSTBS-FARM-ONC-MERIDIAN-2020 | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Multiparametric assessment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study | |||||||||||||
Medical condition: PATIENTS WITH BONE METASTASIS FROM PROSTATIC CARCINOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001253-41 | Sponsor Protocol Number: GOIM16002-CABONESTUDY | Start Date*: 2018-03-12 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE | |||||||||||||
Full Title: Impact of cabazitaxel on metastatic bone disease in patients with castration resistant prostate cancer previously treated with docetaxel | |||||||||||||
Medical condition: 1. Histologically or cytologically confirmed adenocarcinoma of prostate that is resistant to hormone therapy and previously treated with a docetaxel containing regimen. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003549-18 | Sponsor Protocol Number: 004/001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Cliniques Universitaires SAINT-LUC | |||||||||||||
Full Title: REDUCTION OF BONE MORBIDITY USING AN ORAL BISPHOSPHONATE IN FIBROUS DYSPLASIA OF BONE (PROFIDYS Trial) | |||||||||||||
Medical condition: Fibrous dysplasia •Study I: patients with fibrous dysplasia of bone, with bone pain intensity above 3 on a visual analogical scale from 0 to 10. •Study II: patients with fibrous dysplasia of bone... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003774-16 | Sponsor Protocol Number: EIFFEL | Start Date*: 2016-06-07 |
Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie ) | ||
Full Title: Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO®) in renal cell carcinoma patients with bone metastases | ||
Medical condition: Renal cell carcinoma patients with bone metastases, with or without visceral metastases. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004513-15 | Sponsor Protocol Number: | Start Date*: 2005-11-28 |
Sponsor Name:Univ. Prof. Dr. Christoph Zielinski | ||
Full Title: ASSESSMENT OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH METASTATIC BREAST CANCER SWITCHED FROM INTRAVENOUS ZOLEDRONIC ACID THERAPY TO ORAL IBANDRONATE | ||
Medical condition: Metastatic bone disease due to breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002180-72 | Sponsor Protocol Number: ML20268 | Start Date*: 2006-06-20 | |||||||||||
Sponsor Name:Roche (Hungary) Ltd. | |||||||||||||
Full Title: Open Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6mg in Patients with Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, with... | |||||||||||||
Medical condition: Patients with Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002335-28 | Sponsor Protocol Number: UMCGABR40641 | Start Date*: 2013-01-07 |
Sponsor Name:University medical centre groningen | ||
Full Title: Evaluation of VEGF expression with 89Zr-bevacizumab PET scan in patients with relapsing multiple myeloma; a feasibility study | ||
Medical condition: patients with relapsing multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004879-13 | Sponsor Protocol Number: UKF2013/12 | Start Date*: 2014-12-08 | |||||||||||||||||||||
Sponsor Name:Universitätsklinikum Freiburg | |||||||||||||||||||||||
Full Title: α-RT; Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. EBRT alone in the treatment of advanced castr... | |||||||||||||||||||||||
Medical condition: Bone metastases in advanced castration resistant prostate carcinoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002802-48 | Sponsor Protocol Number: ML 18107 | Start Date*: 2006-09-22 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: Evaluation of efficacy and safety of i.v. and oral ibandronate in elderly patients with bone metastases from solid tumors. A randomised phase II study | |||||||||||||
Medical condition: Treatment of bone metastases in elderly patients with solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004430-96 | Sponsor Protocol Number: 201600107 | Start Date*: 2017-12-11 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk | ||
Medical condition: Testicular cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005666-37 | Sponsor Protocol Number: ODX-003 | Start Date*: 2016-02-26 | |||||||||||
Sponsor Name:DexTech Medical AB | |||||||||||||
Full Title: A randomized, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases | |||||||||||||
Medical condition: Metastatic Castration Resistant Prostate Cancer (CRPC) and skeletal metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) EE (Completed) LV (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
